Franco Celina, Andersson Björn, Lönn Lars, Bengtsson Bengt-Ake, Svensson Johan, Johannsson Gudmundur
Department of Endocrinology, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden.
J Clin Endocrinol Metab. 2007 Jul;92(7):2644-7. doi: 10.1210/jc.2007-0068. Epub 2007 Apr 24.
Abdominal obesity is associated with low GH secretion, elevated circulating markers of inflammation, and increased risk of cardiovascular disease.
The objective was to study the effect of GH treatment on inflammatory markers and vascular adhesion molecules in postmenopausal women with abdominal obesity.
Forty women aged 51-63 yr received GH (0.67 mg/d) in a randomized, double-blind, placebo-controlled, 12-month trial. Measurements of inflammatory markers [highly sensitive C-reactive protein (CRP), IL-6, and amyloid polypeptideA] and markers of endothelial dysfunction (soluble E-selectin, vascular adhesion molecule-1, intercellular molecule-1, and matrix metalloproteinase-9) were performed at baseline and after 6 and 12 months of treatment.
After 12 months, the mean IGF sd score was 0.9 +/- 1.5 and -0.8 +/- 0.6 in the GH and placebo groups, respectively. GH treatment reduced CRP and IL-6 levels compared with placebo (P = 0.03 and P = 0.05, respectively), whereas the markers of endothelial dysfunction were unaffected. Within the GH-treated group, a reduction was shown in CRP (4.3 +/- 4 to 3.0 +/- 3 mg/liter; P < 0.05) and in IL-6 (4.4 +/- 2 to 3.3 +/- 2 ng/liter; P < 0.01). In the GH-treated group, the decrease in CRP and IL-6 correlated with a reduction in visceral adipose tissue (r = 0.7, P < 0.001 and r = 0.5, P < 0.05, respectively).
GH treatment in postmenopausal women with abdominal obesity reduced serum markers of systemic inflammation. Circulating markers of endothelial dysfunction were unaffected by treatment.
腹部肥胖与生长激素（GH）分泌减少、循环炎症标志物升高以及心血管疾病风险增加有关。
研究GH治疗对绝经后腹部肥胖女性炎症标志物和血管黏附分子的影响。
40名年龄在51 - 63岁的女性参与了一项随机、双盲、安慰剂对照的12个月试验，接受GH（0.67毫克/天）治疗。在基线以及治疗6个月和12个月后，检测炎症标志物[高敏C反应蛋白（CRP）、白细胞介素-6（IL-6）和淀粉样多肽A]以及内皮功能障碍标志物（可溶性E选择素、血管细胞黏附分子-1、细胞间黏附分子-1和基质金属蛋白酶-9）。
12个月后，GH组和安慰剂组的平均胰岛素样生长因子标准差评分分别为0.9±1.5和 - 0.8±0.6。与安慰剂相比，GH治疗降低了CRP和IL-6水平（分别为P = 0.03和P = 0.05），而内皮功能障碍标志物未受影响。在接受GH治疗的组内，CRP（从4.3±4降至3.0±3毫克/升；P < 0.05）和IL-6（从4.4±2降至3.3±2纳克/升；P < 0.01）有所降低。在接受GH治疗的组中，CRP和IL-6的降低与内脏脂肪组织的减少相关（分别为r = 0.7，P < 0.001和r = 0.5，P < 0.05）。
对绝经后腹部肥胖女性进行GH治疗可降低全身炎症的血清标志物。治疗未影响循环中的内皮功能障碍标志物。
